In addition, the downregulation of CPT2 in colorectal cancer can promote cancer stemness and oxaliplatin (chemotherapy drug) resistance through the activation of the Wnt/β-catenin pathway by inducing glycolytic metabolism (201). Here, CPT2 is linked to cancer.